Synthesis and evaluation of antitumor activities of novel chiral 1,2,4-triazole Schiff bases bearing γ-butenolide moiety. 2012

Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
Key Laboratory of Energy Sources & Chemical Engineering, Development Center of Natural Products and Medication and School of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, 750021, China. lixq@nxu.edu.cn.

BACKGROUND 1,2,4-Triazole derivatives have received much attention due to their versatile biological properties including antibacterial, antifungal, anticonvulsant, antiinflammatory, anticancer, and antiproliferative properties. 1,2,4-Triazole nucleus has been incorporated into a wide variety of therapeutically interesting molecules to transform them into better drugs. Schiff bases of 1,2,4-triazoles have also been found to possess extensive biological activities. On the other hand, γ-substituted butenolide moiety represents a biological important entity that is present in numerous biologically active natural products. RESULTS We have described herein the synthesis of 12 hybrid 1,2,4-triazole Schiff bases bearing γ-substituted butenolide moiety. These compounds were synthesized by utilizing the tandem asymmetric Michael addition/elimination reaction as the key step. All the new compounds were evaluated for their in vitro anticancer activity. CONCLUSIONS Tandem asymmetric Michael addition/elimination approach has offered an easy access to new chiral 1,2,4-triazole compounds 7a-7l. All these chiral 1,2,4-triazole derivatives exhibited good anticancer activities towards Hela. Of all the tested compounds, the chiral compound 7l with an IC50 of 1.8 μM was found to be the most active.

UI MeSH Term Description Entries

Related Publications

Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
December 2017, Journal of enzyme inhibition and medicinal chemistry,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
November 2016, Annales pharmaceutiques francaises,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
December 2014, Journal of enzyme inhibition and medicinal chemistry,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
August 2018, Molecular diversity,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
January 2015, Iranian journal of pharmaceutical research : IJPR,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
November 2009, European journal of medicinal chemistry,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
January 2016, Chemical & pharmaceutical bulletin,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
August 2012, European journal of medicinal chemistry,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
October 2018, Bioorganic chemistry,
Xiang Li, and Xue-Qiang Li, and He-Mei Liu, and Xue-Zhang Zhou, and Zhi-Hui Shao
July 2007, Molecules (Basel, Switzerland),
Copied contents to your clipboard!